Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking ...

Essentially, cereblon and its target proteins can change shape to form a complex with the cereblon, the target, and the ...

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, has made significant advancements in drug discovery as highlighted in a cover article published in Science. The research ...

Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) rallied 49% Monday morning after the biotech signed an exclusive license deal with Novartis (NYSE:NVS) to advance its VAV1-directed molecular glue ...

Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with a potential $2.1 billion in milestone payments.

Monte Rosa Therapeutics signed a development and commercialization deal with Novartis that could pay the biotech up to $2.1 billion. The agreement is for Monte Rosa's MRT-6160 drug and other ...

Explore Monte Rosa Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for GLUE.

Monte Rosa will also be eligible for future payments of up to $2.1 billion as well as royalties on net sales outside the U.S. Shares of Monte Rosa surged 32% to $6.46 in premarket trade following ...

From what we can see, insiders were net buyers in Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.

Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies, and tiered royalties on ex-U.S. net sales.

BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...